These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38476849)

  • 1. Impact of zolpidem and lemborexant on sleep and morning symptoms when used as a single dose for polysomnography.
    Sawatari H; Yoshikawa T; Ando SI
    Sleep Biol Rhythms; 2024 Jan; 22(1):155-158. PubMed ID: 38476849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
    Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
    JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder.
    Moline M; Zammit G; Cheng JY; Perdomo C; Kumar D; Mayleben D
    J Clin Sleep Med; 2021 Jun; 17(6):1167-1174. PubMed ID: 33590823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the treatment effectiveness between lemborexant and zolpidem tartrate extended-release for insomnia disorder subtypes defined based on polysomnographic findings.
    Inoue Y; Nishida M; Kubota N; Koebis M; Taninaga T; Muramoto K; Ishikawa K; Moline M
    J Clin Sleep Med; 2023 Mar; 19(3):519-528. PubMed ID: 36472134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening.
    Murphy P; Kumar D; Zammit G; Rosenberg R; Moline M
    J Clin Sleep Med; 2020 May; 16(5):765-773. PubMed ID: 32022664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
    Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
    Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: a model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents.
    Ikeda S; Azuma MK; Fujimoto K; Shibahara H; Inoue S; Moline M; Ishii M; Mishima K
    Psychol Med; 2022 Oct; 52(13):2822-2834. PubMed ID: 35506334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.
    Citrome L; Juday T; Frech F; Atkins N
    J Clin Psychiatry; 2021 Jun; 82():. PubMed ID: 34077032
    [No Abstract]   [Full Text] [Related]  

  • 9. Exposure-Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia.
    Lalovic B; Savant Landry I; Moline M; Reyderman L; Hussein Z
    J Clin Pharmacol; 2023 Apr; 63(4):498-511. PubMed ID: 36524428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials.
    Gotfried MH; Auerbach SH; Dang-Vu TT; Mishima K; Kumar D; Moline M; Malhotra M
    Drugs Aging; 2024 Sep; 41(9):741-752. PubMed ID: 39120786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials.
    Moline M; Zammit G; Yardley J; Pinner K; Kumar D; Perdomo C; Cheng JY
    Postgrad Med; 2021 Jan; 133(1):71-81. PubMed ID: 33119423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lemborexant Attenuates Regurgitation without Worsening Objective Parameters on Reflux Monitoring in Patients with Gastroesophageal Reflux Disease and Insomnia: A Single-Arm Proof-of-Concept Study.
    Hoshikawa Y; Momma E; Kawami N; Iwakiri K
    Digestion; 2023; 104(6):438-445. PubMed ID: 37429270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings.
    Roth T; Hull SG; Lankford DA; Rosenberg R; Scharf MB;
    Sleep; 2008 Sep; 31(9):1277-84. PubMed ID: 18788653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia.
    Staner C; Joly F; Jacquot N; Vlasova ID; Nehlin M; Lundqvist T; Edenius C; Staner L
    Curr Med Res Opin; 2010 Jun; 26(6):1423-31. PubMed ID: 20397964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the Real-World, Long-Term Impact of Lemborexant on Sleep Quality in a Home-Based Clinical Study.
    Miyata S; Iwamoto K; Okada I; Fujimoto A; Kogo Y; Mori D; Amano M; Matsuyama N; Nishida K; Ando M; Taoka T; Naganawa S; Ozaki N
    Nat Sci Sleep; 2024; 16():291-303. PubMed ID: 38524766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.
    Murphy P; Moline M; Mayleben D; Rosenberg R; Zammit G; Pinner K; Dhadda S; Hong Q; Giorgi L; Satlin A
    J Clin Sleep Med; 2017 Nov; 13(11):1289-1299. PubMed ID: 29065953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of lemborexant 5 mg versus 10 mg for the treatment of insomnia: a systematic review.
    Habiba U; Waseem R; Shaikh TG; Waseem S; Ahmed SH; Asghar MS
    Neurol Sci; 2023 May; 44(5):1533-1541. PubMed ID: 36633778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory Safety of Lemborexant in Healthy Subjects: A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Crossover Study.
    Cheng JY; Moline M; Zammit GK; Filippov G; Bsharat M; Hall N
    Clin Drug Investig; 2021 May; 41(5):449-457. PubMed ID: 33723806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zolpidem, but lemborexant more consistently, showed self-reported and objective benefits compared with placebo in insomnia patients with sleep duration of less than 6 hours per night.
    Juginović A
    J Clin Sleep Med; 2023 Mar; 19(3):429-430. PubMed ID: 36635968
    [No Abstract]   [Full Text] [Related]  

  • 20. Relationship between zolpidem concentrations and sleep parameters in pediatric burn patients.
    Stockmann C; Gottschlich MM; Healy D; Khoury JC; Mayes T; Sherwin CM; Spigarelli MG; Kagan RJ
    J Burn Care Res; 2015; 36(1):137-44. PubMed ID: 25185933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.